BeneFIX

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
BeneFIX
Generic name
COAGULATION FACTOR IX (RECOMBINANT)
Manufacturer
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
Product type
PLASMA DERIVATIVE
SPL set ID
85faa5bc-cee5-4ef1-8d80-bdbcb7eba1e4
SPL ID
3b0657cb-0070-4c64-b72c-2518178805e7
Version
45
Effective date
2025-02-24
Source export date
2026-11-13
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:33:15

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment with the product and seek emergency treatment. Patients may develop hypersensitivity to hamster (CHO) protein as BeneFIX contains trace amounts. ( 5.1 ) • BeneFIX has been associated with the development of thromboembolic complications, including in patients receiving continuous infusion through a central venous catheter. ( 5.2 ) • Nephrotic syndrome has been reported following immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of allergic reactions to factor IX. ( 5.3 ) • Development of neutralizing antibodies (inhibitors) to BeneFIX may occur. If expected plasma factor IX activity levels are not attained, or if patient presents with allergic reaction, or if bleeding is not controlled with an expected dose, perform an assay that measures factor IX inhibitor concentration. ( 5.4 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFIX and have manifested as pruritus, rash, urticaria, hives, facial swelling, dizziness, hypotension, nausea, chest discomfort, cough, dyspnea, wheezing, flushing, discomfort (generalized) and fatigue. Frequently, these events have occurred in close temporal association with the development of factor IX inhibitors. Closely monitor patients for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product. Because of the potential for allergic reactions with factor IX concentrates, perform the initial (approximately 10 – 20) administrations of factor IX under medical supervision where proper medical care for allergic reactions could be provided. Advise patients to discontinue use of the product and contact their physician and/or seek immediate emergency care. Immediately discontinue the administration and initiate appropriate treatment if symptoms occur. BeneFIX contains trace amounts of hamster (CHO) proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. 5.2 Thromboembolic Complications There have been post-marketing reports of thrombotic events in patients receiving continuous-infusion BeneFIX through a central venous catheter, including life-threatening superior vena cava (SVC) syndrome in critically ill neonates [see Adverse Reactions (6.2) ] . The safety and efficacy of BeneFIX administration by continuous infusion have not been established [see Dosage and Administration (2.1 , 2.3) ] . 5.3 Nephrotic Syndrome Nephrotic syndrome has been reported following immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of allergic reactions to factor IX. The safety and efficacy of using BeneFIX for immune tolerance induction have not been established. 5.4 Neutralizing Antibodies (Inhibitors) Neutralizing antibodies (inhibitors) have been reported following administration of BeneFIX [see Adverse Reactions (6.1) ] . Evaluate patients using BeneFIX for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected plasma factor IX activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor IX inhibitor concentration. Patients with factor IX inhibitors are at an increased risk of severe hypersensitivity reactions or anaphylaxis upon subsequent challenge with factor IX. 2 Evaluate patients experiencing allergic reactions for the presence of an inhibitor and closely monitor patients with inhibitors for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product [see Warnings and Precautions (5.1) ] . 5.5 Monitoring Laboratory Tests • Monitor patients for factor IX activity levels by the one-stage clotting assay to confirm that adequate factor IX levels have been achieved and maintained, when clinically indicated [see Dosage and Administration (2.1) ] . • Monitor patients for the development of inhibitors if expected plasma factor IX activity levels are not attained, or if bleeding is not controlled with the recommended dose of BeneFIX. Determine plasma factor IX inhibitor levels in Bethesda Units (BUs).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most serious adverse reactions are systemic hypersensitivity reactions, including bronchospastic reactions and/or hypotension and anaphylaxis and the development of high-titer inhibitors necessitating alternative treatments to factor IX replacement therapy. The most common adverse reactions observed in clinical trials [frequency >5% of previously treated patients (PTPs) or previously untreated patients (PUPs)] were fever, cough, headaches, dizziness, nausea, injections site reaction, injection site pain and skin-related hypersensitivity reactions (e.g., rash, hives). The most common adverse reactions (incidence >5%) from clinical trials were fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness and rash. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals LLC at 1-800-934-5556 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. During uncontrolled, open-label clinical trials with BeneFIX conducted in PTPs, 113 adverse reactions with known or unknown relation to BeneFIX therapy were reported among 38.5% (25 of 65) of subjects (with some subjects reporting more than one event) who received a total of 7,573 infusions. These adverse reactions are summarized in Table 2. Table 2: Adverse Reactions Reported for PTPs Adverse reactions reported within 72 hours of an infusion of BeneFIX. Body System Adverse Reaction Number of Patients (%) Blood and lymphatic system disorders Factor IX inhibition Low-titer transient inhibitor formation. 1 (1.5%) Eye disorders Blurred vision 1 (1.5%) Gastrointestinal disorders Nausea 4 (6.2%) Vomiting 1 (1.5%) General disorders and administration site conditions Injection site reaction 5 (7.7%) Injection site pain 4 (6.2%) Fever 2 (3.1%) Infections and infestations Cellulitis at IV site 1 (1.5%) Phlebitis at IV site 1 (1.5%) Nervous system disorders Headache 7 (10.8%) Dizziness 5 (7.7%) Taste perversion (altered taste) 3 (4.6%) Shaking 1 (1.5%) Drowsiness 1 (1.5%) Renal and urinary disorders Renal infarct The renal infarct developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode. The relationship of the infarct to the prior administration of BeneFIX is uncertain. 1 (1.5%) Respiratory, thoracic and mediastinal disorders Dry cough 1 (1.5%) Hypoxia 1 (1.5%) Chest tightness 1 (1.5%) Skin and subcutaneous disorders Rash 4 (6.2%) Hives 2 (3.1%) Vascular disorders Flushing 2 (3.1%) In the 63 PUPs, who received a total of 5,538 infusions, 10 adverse reactions were reported among 9.5% of the patients (6 out of 63) having known or unknown relationship to BeneFIX. These events are summarized in Table 3. Table 3: Adverse Reactions Reported for PUPs Adverse reactions reported within 72 hours of an infusion of BeneFIX. Body System Adverse Reaction Number of Patients (%) Blood and lymphatic system disorders Factor IX inhibition Two subjects developed high-titer inhibitor formation during treatment with BeneFIX. 2 (3.2%) General disorders and administration site conditions Injection site reaction 1 (1.6%) Chills 1 (1.6%) Respiratory, thoracic and mediastinal disorders Dyspnea (respiratory distress) 2 (3.2%) Skin and subcutaneous disorders Hives 3 (4.8%) Rash 1 (1.6%) In a multi-center, prospective, open-label clinical trial with BeneFIX administered at 100 IU/kg once weekly, 25 PTPs (exposed to a factor IX containing product for ≥100 exposure days) were evaluated, with 25 subjects treated for approximately 52 weeks. Common (≥5%) adverse reactions were headache (36%), fever (20%), and cough (8%). No subject was withdrawn from the trial due to an adverse reaction. In the trial, no inhibitors were detected and no thrombotic events or anaphylactic reactions were reported. Immunogenicity In clinical trials with 65 PTPs (defined as having more than 50 exposure days), a low-titer inhibitor was observed in one patient. The inhibitor was transient, the patient continued on the trial and had normal factor IX recovery at the trial completion (approximately 15 months after inhibitor detection). In clinical trials with pediatric PUPs, inhibitor development was observed in 2 out of 63 patients (3.2%), both were high-titer (>5 BU) inhibitors detected after 7 and 15 exposure days, respectively. Both patients were withdrawn from the trial. In a clinical trial of 25 PTPs, with BeneFIX administered at 100 IU/kg once weekly, no inhibitors were detected. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to BeneFIX with the incidence of antibodies to other products may be misleading. Thromboembolic complications All subjects participating in the PTP, PUP and surgery trials were monitored for clinical evidence of thrombosis. No thrombotic complications were reported in PUPs or surgery subjects. One PTP subject experienced a renal infarct (see Table 2 ). Laboratory studies of thrombogenicity (fibrinopeptide A and prothrombin fragment 1 + 2) were obtained in 41 PTPs and 7 surgery subjects prior to infusion and up to 24 hours following infusion. The results of these studies were inconclusive. Out of 29 PTP subjects noted to have elevated fibrinopeptide A levels post-infusion of BeneFIX, 22 also had elevated levels at baseline. Surgery subjects showed no evidence of significant increase in coagulation activation. 6.2 Postmarketing Experience The following post-marketing adverse reactions have been reported for BeneFIX: inadequate factor IX recovery, inadequate therapeutic response, inhibitor development [see Clinical Pharmacology (12) ] , anaphylaxis [see Warnings and Precautions (5.1) ] , angioedema, dyspnea, hypotension, and thrombosis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. There have been post-marketing reports of thrombotic events, including life-threatening SVC syndrome in critically ill neonates, while receiving continuous-infusion BeneFIX through a central venous catheter. Cases of peripheral thrombophlebitis and DVT have also been reported. In some, BeneFIX was administered via continuous infusion, which is not an approved method of administration [see Dosage and Administration (2) ] . The safety and efficacy of BeneFIX administration by continuous infusion have not been established [see Warnings and Precautions (5.2) ] .

adverse reactions table

<table ID="_Reftable2" width="75%"><caption>Table 2: Adverse Reactions Reported for PTPs<footnote ID="_Reft2f1">Adverse reactions reported within 72 hours of an infusion of BeneFIX.</footnote></caption><col width="31%"/><col width="30%"/><col width="26%"/><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Body System</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Reaction</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Number of Patients (%)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Blood and lymphatic system disorders</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>Factor IX inhibition<footnote ID="_Reft2f2">Low-titer transient inhibitor formation.</footnote></paragraph></td><td align="center" styleCode="Rrule Toprule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Eye disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Blurred vision</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Gastrointestinal disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4 (6.2%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>General disorders and administration site conditions</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Injection site reaction</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>5 (7.7%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Injection site pain</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4 (6.2%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Fever</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2 (3.1%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Infections and infestations</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Cellulitis at IV site</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Phlebitis at IV site</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Nervous system disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>7 (10.8%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Dizziness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>5 (7.7%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Taste perversion (altered taste)</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>3 (4.6%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Shaking</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Drowsiness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Renal and urinary disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Renal infarct<footnote ID="_Reft2f3">The renal infarct developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode. The relationship of the infarct to the prior administration of BeneFIX is uncertain.</footnote></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Respiratory, thoracic and mediastinal disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Dry cough</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Hypoxia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Chest tightness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.5%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Skin and subcutaneous disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Rash</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4 (6.2%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Hives</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2 (3.1%)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Vascular disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Flushing</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2 (3.1%)</paragraph></td></tr></tbody></table>

adverse reactions table

<table ID="_Reftable3" width="75%"><caption>Table 3: Adverse Reactions Reported for PUPs<footnote ID="_Reft3f1">Adverse reactions reported within 72 hours of an infusion of BeneFIX.</footnote></caption><col width="31%"/><col width="30%"/><col width="26%"/><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Body System</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Reaction</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Number of Patients (%)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Blood and lymphatic system disorders</paragraph></td><td styleCode="Rrule Toprule Botrule " valign="top"><paragraph>Factor IX inhibition<footnote ID="_Reft3f2">Two subjects developed high-titer inhibitor formation during treatment with BeneFIX.</footnote></paragraph></td><td align="center" styleCode="Rrule Toprule Botrule " valign="top"><paragraph>2 (3.2%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>General disorders and administration site conditions</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Injection site reaction</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.6%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Chills</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.6%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Respiratory, thoracic and mediastinal disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Dyspnea (respiratory distress)</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2 (3.2%)</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Skin and subcutaneous disorders</paragraph></td><td styleCode="Rrule Botrule " valign="top"><paragraph>Hives</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>3 (4.8%)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"/><td styleCode="Rrule Botrule " valign="top"><paragraph>Rash</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1 (1.6%)</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.